Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates

Abstract

Objective:

Previous studies suggest that darbepoetin might stimulate erythropoiesis in preterm neonates more effectively if injected subcutaneously (s.c.) than if infused intravenously (i.v.). It has been postulated that this is because very high plasma concentrations after i.v. dosing result in urinary loss of the drug. However, this theory has not been tested systematically, and no direct comparisons have been made between s.c. and i.v. dosing of darbepoetin in preterm neonates.

Study design:

Preterm neonates were eligible for this pilot study if they were born at 32 weeks gestation with a weight of 1500 g, and had a hemoglobin 10.5 g/dl. The darbepoetin was given (4 μg/kg) i.v., over 4 h, if an i.v. was already in place and s.c. if no i.v. was in place. Urine was collected for drug quantification before dosing and for 48 h after. Blood was obtained for immature reticulocyte fraction (IRF), absolute reticulocyte count (ARC) and reticulocyte % before and 96 h after dosing.

Results:

Ten preterm neonates were studied: five received i.v. and five received s.c. darbepoetin. No adverse effects of the administrations were detected. IRF, ARC and reticulocyte % increased in the i.v. and s.c. recipients, and no difference in magnitude of increase was apparent between the groups. Before the darbepoetin was administered, none of the patients had any erythropoietin (Epo) detected in their urine. After i.v. dosing, no darbepoetin was detected in any of the samples, on any of the subjects, over the subsequent 48 h. After s.c. dosing, three of the patients had minimal urinary Epo detected. The patient with the largest urinary loss of drug had only 0.13% of the administered dose detected in the urine. Thus, essentially no urinary loss of drug was observed following either i.v. or s.c. darbepoetin dosing.

Conclusion:

Darbepoetin loss into the urine was below detectable limits among seven patients, while three had minimally detectable urinary losses. i.v. and s.c. dosing resulted in approximately equivalent increases in reticulocyte response when measured 96 h after dosing. On this basis, we speculate that if a patient who is to receive darbepoetin has an i.v. in place, the drug can be given i.v., thus avoiding any discomfort associated with an s.c. injection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA . Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290–299.

    Article  CAS  Google Scholar 

  2. Cersosimo RJ, Jacobson DR . Epoietin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006; 40: 58–65.

    Article  CAS  Google Scholar 

  3. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol 2005; 25: 725–730.

    Article  CAS  Google Scholar 

  4. Warwood TL, Ohls RK, Lambert DK, Jones C, Scoffield SH, Gupta N et al. Intravenous administration of darbepoetin to NICU patients. J Perinatol 2006; 26: 296–300.

    Article  CAS  Google Scholar 

  5. www.aranesp.com.

  6. McIntosh S . Erythropoietin excretion in the premature infant. J Pediatr 1975; 86: 202–206.

    Article  CAS  Google Scholar 

  7. Buhrer C, Obladen M, Maier R, Muller C . Urinary losses of recombinant erythropoietin in preterm infants. J Pediatr 2003; 142: 452–453 (letter).

    Article  Google Scholar 

  8. Davis BH, Ornvold K, Bigelow NC . Flow cytometric reticulocyte maturity index: a useful laboratory parameter of erythropoietic activity in anemia. Cytometry 1995; 22: 35–39.

    Article  CAS  Google Scholar 

  9. Jelkmann W . The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69: 265–274.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the NICU nurses at the McKay-Dee NICU for their valuable assistance with this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R D Christensen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warwood, T., Ohls, R., Lambert, D. et al. Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates. J Perinatol 26, 636–639 (2006). https://doi.org/10.1038/sj.jp.7211596

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.jp.7211596

Keywords

This article is cited by

Search

Quick links